Bivalirudin

Jump to navigation Jump to search
Bivalirudin
ANGIOMAX® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Bivalirudin
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

For patient information about Bivalirudin, click here.

Synonyms / Brand Names: ANGIOMAX®

Overview

Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).[1]

Chemically, it is a synthetic congener of the naturally occurring drug hirudin (found in the saliva of the medicinal leech Hirudo medicinalis).

Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin.[1][2][3] It inhibits both circulating and clot-bound thrombin,[3] while also inhibiting thrombin-mediated platelet activation and aggregation.[4] Bivalirudin has a quick onset of action and a short half-life.[1] It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).[1] It does not require a binding cofactor such as antithrombin and does not activate platelets.[2][5] These characteristics make bivalirudin an ideal alternative to heparin.

Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials.[1][3][4][6][7]

Category

FDA Package Insert

Label Title

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

References

  1. 1.0 1.1 1.2 1.3 1.4 "Angiomax (bivalirudin) Prescribing Information" (PDF). The Medicines Company. Retrieved 2 December 2011.[dead link]
  2. 2.0 2.1 PMID 17659921 (PMID 17659921)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  3. 3.0 3.1 3.2 PMID 2384594 (PMID 2384594)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  4. 4.0 4.1 PMID 17124018 (PMID 17124018)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  5. PMID 11967385 (PMID 11967385)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  6. PMID 11717596 (PMID 11717596)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  7. PMID 12588269 (PMID 12588269)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand